Compare
Halozyme Therapeutics, Inc. vs Novavax Inc vs Moderna, Inc. vs BioCryst Pharmaceuticals Inc
| Latest fiscal year | Halozyme Therapeutics, Inc. HALO | Novavax Inc NVAX | Moderna, Inc. MRNA | BioCryst Pharmaceuticals Inc BCRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.40B | $1.12B | $1.94B | $874.84M |
| Revenue growth (YoY) | +37.6% | +64.7% | -39.9% | +94.1% |
| Gross margin | 83.6% (computed) | 93.5% (computed) | 55.3% (computed) | n/a |
| Operating margin | 33.6% | 40.3% | -158.1% | 39.0% |
| Net margin | 22.7% | 39.2% | -145.2% | 30.2% |
| Net income | $316.89M | $440.30M | -$2.82B | $263.86M |
| EPS (Diluted) | $2.56 | $2.58 | -$7.26 | $1.21 |
| Operating cash flow | $651.56M | -$244.63M | -$1.87B | $347.37M |
| Free cash flow | $644.59M | n/a | -$2.06B | $344.90M |
| Cash & equivalents | $133.82M | $240.63M | $2.60B | $89.74M |
| Total assets | $2.53B | $1.18B | $12.34B | $514.16M |
| Total liabilities | $2.48B | $1.30B | $3.69B | $633.31M |
| Shareholders' equity | $48.81M | -$127.75M | $8.65B | -$119.15M |
| Return on year-end equity | 649.2% | n/a | -32.6% | n/a |
| Shares outstanding | 117.78M | 162.58M | 394.00M | 213.06M |
Revenue, most recent five fiscal years
| Fiscal year | Halozyme Therapeutics, Inc. | Novavax Inc | Moderna, Inc. | BioCryst Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | $1.40B Ended 2025-12-31 | $1.12B Ended 2025-12-31 | $1.94B Ended 2025-12-31 | $874.84M Ended 2025-12-31 |
| 1 year earlier | $1.02B Ended 2024-12-31 | $682.16M Ended 2024-12-31 | $3.24B Ended 2024-12-31 | $450.71M Ended 2024-12-31 |
| 2 years earlier | $829.25M Ended 2023-12-31 | $983.71M Ended 2023-12-31 | $6.85B Ended 2023-12-31 | $331.41M Ended 2023-12-31 |
| 3 years earlier | $660.12M Ended 2022-12-31 | $1.98B Ended 2022-12-31 | $19.26B Ended 2022-12-31 | $270.83M Ended 2022-12-31 |
| 4 years earlier | $443.31M Ended 2021-12-31 | $1.15B Ended 2021-12-31 | $18.47B Ended 2021-12-31 | $157.17M Ended 2021-12-31 |